1 not yet recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Jin Li: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment Fluzoparib, Apatinib - Relapsed Ovarian Cancer | Phase 2 | Not yet recruiting | Jin Li | 54 | 2023-10-30 | 2023-10-13 |
apatinib (1) · fluzoparib (1)